- Home
- ANVS vs QNCX Comparison
ANVS vs QNCX Comparison
Compare ANVS & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANVS
- QNCX
- Stock Information
- Founded
- ANVS 2008
- QNCX 2012
- Country
- ANVS United States
- QNCX United States
- Employees
- ANVS N/A
- QNCX N/A
- Industry
- ANVS Biotechnology: Pharmaceutical Preparations
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ANVS Health Care
- QNCX Health Care
- Exchange
- ANVS Nasdaq
- QNCX Nasdaq
- Market Cap
- ANVS 53.3M
- QNCX 88.6M
- IPO Year
- ANVS 2020
- QNCX 2019
- Fundamental
- Price
- ANVS $2.02
- QNCX $1.56
- Analyst Decision
- ANVS Strong Buy
- QNCX Strong Buy
- Analyst Count
- ANVS 3
- QNCX 6
- Target Price
- ANVS $13.50
- QNCX $8.00
- AVG Volume (30 Days)
- ANVS 621.6K
- QNCX 225.9K
- Earning Date
- ANVS 11-12-2025
- QNCX 11-12-2025
- Dividend Yield
- ANVS N/A
- QNCX N/A
- EPS Growth
- ANVS N/A
- QNCX N/A
- EPS
- ANVS N/A
- QNCX N/A
- Revenue
- ANVS N/A
- QNCX N/A
- Revenue This Year
- ANVS N/A
- QNCX N/A
- Revenue Next Year
- ANVS N/A
- QNCX N/A
- P/E Ratio
- ANVS N/A
- QNCX N/A
- Revenue Growth
- ANVS N/A
- QNCX N/A
- 52 Week Low
- ANVS $1.11
- QNCX $0.72
- 52 Week High
- ANVS $8.93
- QNCX $2.45
- Technical
- Relative Strength Index (RSI)
- ANVS 48.58
- QNCX 37.12
- Support Level
- ANVS $1.90
- QNCX $1.55
- Resistance Level
- ANVS $2.17
- QNCX $1.63
- Average True Range (ATR)
- ANVS 0.15
- QNCX 0.09
- MACD
- ANVS 0.00
- QNCX -0.03
- Stochastic Oscillator
- ANVS 35.66
- QNCX 13.95
About ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.